Related Experiment Videos

Barriers to care of chronic hepatitis patients in Latin America

Edna Strauss1

  • 1Internal Medicine, School of Medicine, University of São Paulo, Brazil. ednastrauss@gmail.com

Archives of Medical Research
|July 7, 2007
PubMed

Insights

Delays in diagnosing chronic hepatitis B (HBV) and hepatitis C (HCV) stem from limited information and diagnostic access. Overcoming these barriers is crucial for effective patient management and treatment success.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Public Health

Background:

  • Chronic hepatitis B (HBV) and hepatitis C (HCV) are prevalent, life-threatening disorders.
  • Delayed diagnosis is a significant issue, often due to lack of patient and physician awareness.
  • Limited availability or underutilization of diagnostic tests by primary care physicians further exacerbates the problem.

Purpose of the Study:

  • To identify and analyze the key barriers to timely diagnosis and effective management of chronic hepatitis B and C.
  • To highlight the challenges in treatment and surveillance for patients with chronic viral hepatitis.

Main Methods:

  • Review of current literature and clinical guidelines on chronic hepatitis B and C diagnosis and management.
  • Analysis of factors contributing to diagnostic delays and treatment challenges.
  • Identification of obstacles in patient care pathways.

Main Results:

  • Lack of information, diagnostic test accessibility, and physician awareness are primary diagnostic barriers.
  • Absence of symptoms in early stages and evolving treatment landscapes complicate management.
  • Absence of an ideal drug (inexpensive, safe, highly effective) and patient/physician concerns about side effects hinder treatment adherence.

Conclusions:

  • Addressing information gaps and improving diagnostic accessibility are critical for early detection of chronic hepatitis B and C.
  • Optimizing surveillance strategies and developing better therapeutic options are essential for improved patient outcomes.
  • Overcoming barriers to treatment adherence, including managing side effects and ensuring access, is vital for successful management of chronic viral hepatitis.

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Barriers to Effective Communication II01:21

Barriers to Effective Communication II

The barriers to effective communication also include cultural barriers, semantic barriers, gender barriers, and time constraints.
Cultural barriers:
Differences in values, beliefs, religion, knowledge, and tradition can significantly impact communication. Awareness of nonverbal cues is critical, especially when conversing with a patient from a different culture. What appears appropriate in one culture may be inappropriate in another.
Semantic barriers:
As a result of their tendency to use...